UPDATE 1-Bluebird prices gene therapy at 1.58 mln euros over 5 years
Bluebird bio Inc on Friday set
a price for its gene therapy, Zynteglo, at 1.58 million euros
($1.78 million) over five years, after winning conditional
approval in Europe this month to treat a rare genetic blood
disorder.
The company proposed an installment plan, with 315,000 euros
paid up front and four additional annual payments due only if
the treatment continues to be effective.
a price for its gene therapy, Zynteglo, at 1.58 million euros
($1.78 million) over five years, after winning conditional
approval in Europe this month to treat a rare genetic blood
disorder.
The company proposed an installment plan, with 315,000 euros
paid up front and four additional annual payments due only if
the treatment continues to be effective.
Posted by Reuters
